Proceeds from the transaction will be used for generalcorporate purposes, including clinical development of the Company’s leadingoncology and endocrinology compounds.Dr Juergen Engel, Ph. D., President and CEO of AEterna Zentaris stated, “Weare very pleased with this vote of confidence from targeted specializedinstitutional investors. In addition, completing this financing provides uswith additional funds that will help us to further strengthen our promisingoncology pipeline.”As of June 24, 2009 and after issuing 5,319,149 common shares at the closingof the offering, the Company had 58,506,619 common shares issued andoutstanding.A shelf registration statement relating to the common shares and warrantsissued in the offering (and the common shares issuable upon exercise of thewarrants) has been filed with the Securities and Exchange Commission (the”SEC”) and has been declared effective. A prospectus supplement relating tothe offering was filed with the SEC. Copies of the prospectus supplement andaccompanying prospectus may be obtained directly from AEterna Zentaris Inc.,1405 du Parc-Technologique Boulevard, Quebec City, Canada G1P 4P5. Thisannouncement is neither an offer to sell nor a solicitation of an offer to buyany of AEterna Zentaris’ common shares or warrants.

No offer, solicitation orsale will be made in any jurisdiction in which such offer, solicitation orsale is unlawful.Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc.,(Nasdaq: RODM), acted as the exclusive placement agent for the transaction.About AEterna Zentaris Inc.AEterna Zentaris Inc. is a global biopharmaceutical company focused onendocrine therapy and oncology, with proven expertise in drug discovery,development and commercialization. News releases and additional informationare available at StatementsThis press release contains forward-looking statements made pursuant to thesafe harbor provisions of the U.S. Securities Litigation Reform Act of 1995.Forward-looking statements involve known and unknown risks and uncertainties,which could cause the Company’s actual results to differ materially from thosein the forward-looking statements. Such risks and uncertainties include, amongothers, the availability of funds and resources to pursue R&D projects, thesuccessful and timely completion of clinical studies, the ability of theCompany to take advantage of business opportunities in the pharmaceuticalindustry, uncertainties related to the regulatory process and general changesin economic conditions. Investors should consult the Company’s quarterly andannual filings with the Canadian and U.S. securities commissions foradditional information on risks and uncertainties relating to theforward-looking statements.

Investors are cautioned not to rely on theseforward-looking statements. The Company does not undertake to update theseforward-looking statements. We disclaim any obligation to update any suchfactors or to publicly announce the result of any revisions to any of theforward-looking statements contained herein to reflect future results, eventsor developments except if we are requested by a governmental authority orapplicable law.SOURCEAETERNA ZENTARIS INC.Investor Relations: Ginette Vallieres, Investor Relations Coordinator, (418)652-8525 ext. 265, ; Media Relations: Paul Burroughs,Director of Communications, (418) 652-8525 ext. 406, . O1 Communications Adds General Manager to Oversee Sales Growth and New OfficeOpeningsSACRAMENTO, Calif., June 24 /PRNewswire/ — O1 Communications, Inc. haspromoted Henri De La Chapelle to General Sales Manager to head the company’sCalifornia sales effort, effective immediately.